



---

Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 13 May 2021

---

## Noxopharm to Present to Share Café Hidden Gems Webinar

**Sydney 13 May 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX)** provides a copy of the presentation to be made by the Company's CEO and Managing Director, Dr Graham Kelly to the Share Cafe Micro/Small Cap "Hidden Gems" webinar series tomorrow, Friday 14 May 2021 from 12.30pm AEST/10.30am AWST.

Dr Kelly will provide an update on the Company's clinical program, including its "4 Pillars" oncology strategy.

To access further details and register for the event (no charge), please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/5416151767246/WN\\_7HSAdeXe3T--VtjAJz1Wejg](https://us02web.zoom.us/webinar/register/5416151767246/WN_7HSAdeXe3T--VtjAJz1Wejg)

A recorded copy of the webinar will be made available following the event.

A copy of the investor presentation to be delivered during the webinar is attached.

---

**-ENDS-**

*Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



# NOXOPHARM CORPORATE PRESENTATION MAY 2021

Dr Graham Kelly  
CEO and Managing Director  
**NOXOPHARM LIMITED (ASX:NOX)**



**Discover**



**Develop**



**Deliver**



# DISCLAIMER



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking


statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

A close-up, blue-tinted photograph of a microscope objective lens. The lens is cylindrical with a textured top ring and a clear glass tip. The numbers "100/1.25" and "160/0" are visible on the lens barrel. The background is a blurred blue bokeh.


# INTRODUCTION

# SNAPSHOT




Source: World Health Organisation (2020)

# LINK BETWEEN CANCER & SEPTIC SHOCK



# NOX BUSINESS OVERVIEW






A 3D digital illustration of a cellular environment. Several large, spherical cells with textured, slightly irregular surfaces are scattered across the frame. The cells are rendered in shades of blue and teal. In the center, one cell is highlighted with a semi-transparent white layer, revealing a cluster of small red spheres inside. Numerous small, Y-shaped blue structures, representing antibodies, are shown floating in the space around the cells, some appearing to interact with the cell surfaces. The background is a dark, deep blue, creating a sense of depth and focus on the cellular structures.

# VEYONDA<sup>®</sup> AND CANCER

Aim is to position Veyonda as a first-in-class booster of major cancer treatments



# VEYONDA® - 4-PILLARS ONCOLOGY PROGRAM



## CEP program

chemotherapy



**\$50 billion**

## IONIC program

checkpoint inhibitors



**\$20 billion**

## DARRT program

external beam radiotherapy



**\$7 billion**

## LuPIN program

targeted drug therapy



**(pred.) \$3 billion**

Approximate global market size (US\$)

Four major commercial opportunities for Veyonda


# VEYONDA® - TUMOUR-FIGHTING COLD TO HOT EFFECT



Effectiveness of current anti-cancer therapies believed limited by absence of an effective immune function inside tumours. Veyonda designed to restore this function



Majority of human tumours are **COLD** (lacking active immune cells)



Converting **COLD** tumors to **HOT** means that standard anti-cancer treatments should work better



Immune cells driven from tumour

**Veyonda** restores immune function to tumour



# VEYONDA® - 4-PILLARS ONCOLOGY PROGRAM



	CEP program	IONIC program	DARRT program	LuPIN program
	<b>chemotherapy</b>	<b>checkpoint inhibitors</b>	<b>external beam radiotherapy</b>	<b>targeted drug therapy</b>
Clinical evidence of Veyonda cancer-boosting effects	Phase 1b trial 	Pre-clinical evidence	Phase 1b trial 	Phase 1b/2a trial  To be completed
Current status	<ul style="list-style-type: none"> <li>Phase 1b trial</li> <li>+ doxorubicin</li> <li>Soft tissue sarcoma</li> <li>40 patients</li> </ul> In planning	<ul style="list-style-type: none"> <li>Phase 1b trial</li> <li>+ Opdivo®</li> <li>30 patients</li> <li>BMS co-sponsor</li> </ul> Due to commence	<ul style="list-style-type: none"> <li>Phase 2 trial</li> <li>+ EBRT</li> <li>Multinational</li> <li>Prostate, breast, lung</li> </ul> In planning	<ul style="list-style-type: none"> <li>+ <sup>177</sup>Lu-PSMA-617</li> <li>Prostate</li> <li>Novartis co-sponsor</li> </ul>

Aim = to position Veyonda as a first-in-class booster of major cancer treatments

### SUMMARY

**We are on-track** with early proof-of-concept found in late-stage cancers in combination with

- chemotherapy (carboplatin)
- radiotherapy
- targeted drug therapy (radiopharmaceutical)


and

- all Veyonda found to be safe and well-tolerated





**We expect major catalyst milestones** over next 18 months

**Success in any 1 of the 4-pillar strategy has the potential to make Veyonda a major breakthrough drug**

# KEY METRICS (at 12 May 2021)



## News Flow (next 6 months)

-  IONIC-1, DARRT-2 & CEP-2 start patient recruitment
-  COVID-19 clinical trial completion
-  Novel drug pipeline
-  Pharmorage progressing novel drug development for chronic inflammation and autoimmunity



## FOR FURTHER INFORMATION:



[info@noxopharm](mailto:info@noxopharm)



[www.noxopharm.com](http://www.noxopharm.com)



[@Noxopharm](https://twitter.com/Noxopharm)



Discover



Develop



Deliver

